Akero Therapeutics nearly doubled Monday — and pulled 89bio shares higher — after the company's treatment for MASH obliterated expectations. SAN FRANCISCO, Jan. 27, 2025 (GLOBE NEWSWIRE ...

“2024 marks a tremendous year of execution and progress for 89bio, highlighted by the initiation of two global pivotal trials targeting advanced MASH patients, as well as completion of ...

Explore 89bio stock price, quotes ... Phase 2 tirzepatide trial shows promising results for MASH treatment. Further trials needed to confirm efficacy and safety.

89Bio Inc ( (ETNB)) has released its Q4 earnings. Here is a breakdown of the information 89Bio Inc presented to its investors. See what stocks are receiving Strong Buy ratings from top-rated analysts.

“2024 marks a tremendous year of execution and progress for 89bio (ETNB), highlighted by the initiation of two global pivotal trials targeting advanced MASH patients, as well as completion of ...

89bio), 3 featured pegbelfermin (BMS-986036, Bristol-Myers Squibb), and the remaining 3 featured efruxifermin (AKR-001, Akero Therapeutics). Fibrosis improvement at or above stage 1, without MASH ...

30, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio ... investor meetings at the H.C. Wainwright 8th Annual MASH Investor Conference on Monday, October 7, 2024 at 11: ...

Data analyses from the Phase 2b ENLIVEN trial highlighting the potential anti-fibrotic effects and the potential utility of non-invasive tests correlating with histological endpoints were presented at ...

ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continue to ...

pre-fund Akero Therapeutics nearly doubled Monday — and pulled 89bio shares higher — after the company's treatment for MASH obliterated expectations. SAN FRANCISCO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- ...